107 SPRING STREET, SEATTLE, WA
Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Elects Directors at 2026 Annual Meeting
Other Events
Annual Report to Security Holders
News
Atossa Therapeutics Enters $50 Million At the Market Offering Agreement
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Delisting Amendment